ACM Biolabs - About the company
ACM Biolabs is a seed company based in Singapore (Singapore), founded in 2012 by Madhavan Nallani. It operates as an Artificial membrane platform for antibody and vaccine production. ACM Biolabs has raised an undisclosed amount in funding from Venturelab and NTUitive. The company has 2269 active competitors, including 531 funded and 393 that have exited. Its top competitors include companies like HOOKIPA Pharma, Atea and Vaxart.
Company Details
ACM Biolabs has developed a proprietary artificial polymer-based cell membrane platform that enables them to embed and stabilize functional membrane proteins in a native-like environment. The embedded proteins are able to elicit strong immune reactions when introduced in the body which makes the platform highly suited to the development of vaccines, as well as for production of antibodies against membrane protein targets. The company is also using this technology to develop targeted drug delivery systems ocular or transdermal delivery.
- Website
- acmbiolabs.com
- Registered Address
- 8 EU TONG SEN STREET #16-98 THE CENTRAL SINGAPORE 059818
Key Metrics
Founded Year
2012
Location
Singapore, Singapore
Stage
Seed
Latest Funding Round
Investors
Ranked
159th among 2269 active competitors
Employee Count
18 as on Aug 31, 2026
Similar Companies
Legal entities associated with ACM Biolabs
ACM Biolabs is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Acm Biolabs Pte. Ltd. UEN: 201317235H , Singapore, Active | Dec 31, 2011 | - | - |
Sign up to download ACM Biolabs' company profile
ACM Biolabs's funding and investors
ACM Biolabs has raised funding over 2 rounds. Its first funding round was on Apr 13, 2016. Its latest funding round was a Seed round on Apr 15, 2021 for $*****. 1 investor participated in its latest round. ACM Biolabs has 8 institutional investors and 2 angel investors.
Here is the list of recent funding rounds of ACM Biolabs:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 15, 2021 | 4345791 | Seed | 9123400 | 8389166 | 5007403 | 4928545 |
Apr 13, 2016 | 7417919 | Seed | 2009795 | 3635755 | 8479046 |
Access funding benchmarks and valuations. Sign up today!View details of ACM Biolabs's funding rounds and investors
ACM Biolabs' founders and board of directors
Founder? Claim ProfileThe founders of ACM Biolabs is Madhavan Nallani. Madhavan Nallani is the CEO of ACM Biolabs.
Here are the details of ACM Biolabs' key team members:
- Madhavan Nallani: Founder & CEO of ACM Biolabs. They serve on the board of 1 company.Contact Info: 1 email address
ACM Biolabs' Board of Directors
ACM Biolabs's board has 3 active members. Madhavan Nallani, Erich Erber and Ong Sang Bin are part of team.Here is the list of ACM Biolabs' board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 13y 2m | |
cyuffpr | Team | - | Current | 2y 3m |
dqunlmj | Team | - | Current | 1y 4m |
dfpqztw | Team | - | Past | 2y 8m |
View details of ACM Biolabs's Founder profiles and Board Members
ACM Biolabs' employee count trend
ACM Biolabs has 18 employees as of Aug 26. Here is ACM Biolabs's employee count trend over the years:
Uncover ACM Biolabs' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ACM Biolabs's Competitors and alternates
Top competitors of ACM Biolabs include HOOKIPA Pharma, Atea and Vaxart. Here is the list of Top 10 competitors of ACM Biolabs, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  HOOKIPA Pharma 2011, Vienna (Austria), Public | Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 69/100 | |
2nd | _1579497693661.png?devicePixelRatio=2&height=30&width=30){kind=logo} Atea 2014, Boston (United States), Public | Developer of therapeutics for viral diseases | $293M | 67/100 | |
3rd | Vaxart 2004, San Francisco (United States), Public | Developer of therapeutic solutions for treating multiple infectious diseases | $58M | 67/100 | |
4th | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
5th | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
6th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
7th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
8th |  Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 63/100 | |
9th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
10th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
159th | ACM Biolabs 2012, Singapore (Singapore), Seed | Artificial membrane platform for antibody and vaccine production | - | 49/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ACM Biolabs's competitors? Click here to see the top ones
ACM Biolabs's Investments and acquisitions
ACM Biolabs has made no investments or acquisitions yet.
Reports related to ACM Biolabs
Here is the latest report on ACM Biolabs's sector:
News related to ACM Biolabs
Media has covered ACM Biolabs for a total of 2 events in the last 1 year, 2 of them have been about company updates.
•
ACM Biolabs Reports Safety in Intramuscular Administration of ACM-CpGPR Newswire•Oct 22, 2025•ACM Biolabs
•
ACM Biolabs Reports Favorable Safety Signals, Early Pharmacodynamics of Intramuscular ACM-CpGPR Newswire•Oct 22, 2025•ACM Biolabs
•
Singapore Boosts Access to mRNA Vaccines Through Innovative Delivery PlatformBioSpectrum Asia•May 13, 2025•ACM Biolabs, CEPI
•
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001CNW•Sep 05, 2023•ACM Biolabs
•
ACM Biolabs Further Strengthens Leadership, Appoints David Lawrence to Board of DirectorsPR Newswire•Apr 11, 2023•ACM Biolabs, Sensorion
•
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial OfficerACROFAN•Feb 26, 2023•Sensorion, Valneva, GSK, AskBio and 2 others
•
Seed capital for ACM Biosciences to advance COVID-19 vaccine into clinical trialsStartupticker•Apr 15, 2021•ACM Biolabs
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ACM Biolabs
Explore our recently published companies
- Frukt AS - Norway based, Unfunded company
- Ojha Sir Gyanshala - Unfunded company
- Ozeku - Unfunded company
- Mainmeditech - China based, 2020 founded, Unfunded company
- MOBYLIZ - France based, 2020 founded, Unfunded company
- Dave Carmack - Unfunded company
